<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="apple-mobile-web-app-capable" content="yes">
<title>Moderator Guide — A Tale of Two Trials</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,600;1,400&family=Outfit:wght@300;400;500;600&family=JetBrains+Mono:wght@400;500;600&display=swap" rel="stylesheet">
<style>
:root {
  --bg:        #0a0e14;
  --surface:   #111720;
  --surface2:  #161e2c;
  --border:    rgba(255,255,255,0.07);
  --amber:     #f0b429;
  --amber-dim: #7a5c12;
  --amber-bg:  rgba(240,180,41,0.07);
  --red:       #ef4444;
  --red-bg:    rgba(239,68,68,0.07);
  --green:     #22c55e;
  --green-bg:  rgba(34,197,94,0.07);
  --blue:      #60a5fa;
  --blue-bg:   rgba(96,165,250,0.07);
  --purple:    #a78bfa;
  --purple-bg: rgba(167,139,250,0.07);
  --text:      #eef2f7;
  --muted:     #8899aa;
  --dim:       #445566;
}

* { box-sizing: border-box; margin: 0; padding: 0; }

body {
  background: var(--bg);
  color: var(--text);
  font-family: 'Outfit', sans-serif;
  font-weight: 300;
  font-size: 15px;
  line-height: 1.7;
  padding-bottom: 80px;
}

/* ── HERO ── */
.hero {
  background: linear-gradient(160deg, #0a0e14 0%, #121a26 50%, #0a0e14 100%);
  border-bottom: 1px solid var(--border);
  padding: 52px 44px 44px;
  position: relative;
  overflow: hidden;
}
.hero::after {
  content: '';
  position: absolute;
  top: -100px; right: -100px;
  width: 500px; height: 500px;
  background: radial-gradient(circle, rgba(167,139,250,0.07) 0%, transparent 65%);
  pointer-events: none;
}
.hero-eyebrow {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  letter-spacing: 0.22em;
  text-transform: uppercase;
  color: var(--purple);
  margin-bottom: 16px;
  display: flex;
  align-items: center;
  gap: 12px;
}
.hero-eyebrow::after {
  content: '';
  height: 1px;
  width: 120px;
  background: rgba(167,139,250,0.3);
}
.hero h1 {
  font-family: 'Playfair Display', serif;
  font-size: clamp(28px, 3.5vw, 46px);
  font-weight: 600;
  letter-spacing: -0.02em;
  line-height: 1.1;
  color: var(--text);
  margin-bottom: 12px;
}
.hero h1 em { font-style: italic; color: var(--purple); }
.hero-sub {
  font-size: 15px;
  color: var(--muted);
  max-width: 620px;
  font-weight: 300;
  line-height: 1.6;
  margin-top: 8px;
}
.hero-meta {
  display: flex;
  gap: 28px;
  margin-top: 28px;
  flex-wrap: wrap;
}
.hmeta { display: flex; flex-direction: column; gap: 3px; }
.hmeta-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  color: var(--dim);
}
.hmeta-val { font-size: 13px; color: var(--muted); font-weight: 500; }

/* ── NAV LINK ── */
.back-link {
  display: inline-flex;
  align-items: center;
  gap: 8px;
  padding: 8px 16px;
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: 6px;
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  color: var(--dim);
  text-decoration: none;
  margin: 20px 44px 0;
  display: inline-flex;
  transition: color 0.2s;
}
.back-link:hover { color: var(--muted); }

/* ── CONTAINER ── */
.container {
  max-width: 920px;
  margin: 0 auto;
  padding: 0 44px;
}

/* ── HOW TO USE ── */
.how-to {
  background: var(--purple-bg);
  border: 1px solid rgba(167,139,250,0.15);
  border-radius: 12px;
  padding: 22px 28px;
  margin: 36px 0 0;
  font-size: 14px;
  color: var(--muted);
  line-height: 1.7;
}
.how-to strong { color: var(--purple); font-weight: 600; }
.how-to .htitle {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.2em;
  color: var(--purple);
  margin-bottom: 10px;
  display: block;
}

/* ── SECTION BLOCKS ── */
.slide-section {
  margin-top: 52px;
}
.slide-section:first-of-type { margin-top: 40px; }

.section-header {
  display: flex;
  align-items: flex-start;
  gap: 16px;
  margin-bottom: 20px;
  padding-bottom: 16px;
  border-bottom: 1px solid var(--border);
}
.slide-tag {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  padding: 4px 10px;
  border-radius: 4px;
  white-space: nowrap;
  flex-shrink: 0;
  margin-top: 5px;
  font-weight: 600;
  letter-spacing: 0.05em;
}
.tag-amber { background: var(--amber-bg); color: var(--amber); border: 1px solid rgba(240,180,41,0.25); }
.tag-red   { background: var(--red-bg);   color: var(--red);   border: 1px solid rgba(239,68,68,0.2); }
.tag-green { background: var(--green-bg); color: var(--green); border: 1px solid rgba(34,197,94,0.2); }
.tag-blue  { background: var(--blue-bg);  color: var(--blue);  border: 1px solid rgba(96,165,250,0.2); }
.tag-purple{ background: var(--purple-bg);color: var(--purple);border: 1px solid rgba(167,139,250,0.2); }
.tag-dim   { background: rgba(255,255,255,0.03); color: var(--dim); border: 1px solid var(--border); }

.section-title {
  font-family: 'Playfair Display', serif;
  font-size: 22px;
  font-weight: 600;
  color: var(--text);
  letter-spacing: -0.01em;
  line-height: 1.2;
}
.section-subtitle {
  font-size: 13px;
  color: var(--dim);
  font-family: 'JetBrains Mono', monospace;
  margin-top: 3px;
}

/* ── QUESTION BLOCKS ── */
.question-block {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: 12px;
  margin-bottom: 16px;
  overflow: hidden;
}
.q-header {
  padding: 18px 22px;
  background: var(--surface2);
  border-bottom: 1px solid var(--border);
  display: flex;
  gap: 14px;
  align-items: flex-start;
}
.q-icon {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  color: var(--amber);
  background: var(--amber-bg);
  border: 1px solid rgba(240,180,41,0.25);
  border-radius: 4px;
  padding: 3px 8px;
  flex-shrink: 0;
  margin-top: 2px;
  font-weight: 600;
}
.q-icon.red    { color: var(--red);   background: var(--red-bg);   border-color: rgba(239,68,68,0.2); }
.q-icon.green  { color: var(--green); background: var(--green-bg); border-color: rgba(34,197,94,0.2); }
.q-icon.purple { color: var(--purple);background: var(--purple-bg);border-color: rgba(167,139,250,0.2); }
.q-icon.blue   { color: var(--blue);  background: var(--blue-bg);  border-color: rgba(96,165,250,0.2); }

.q-text {
  font-size: 15px;
  color: var(--text);
  font-weight: 500;
  line-height: 1.5;
  font-style: italic;
  font-family: 'Playfair Display', serif;
}

.q-body {
  padding: 0;
}

/* ── RESPONSE ROWS ── */
.response-row {
  padding: 16px 22px;
  border-bottom: 1px solid var(--border);
  display: grid;
  grid-template-columns: 160px 1fr;
  gap: 16px;
  align-items: flex-start;
}
.response-row:last-child { border-bottom: none; }

.response-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  padding-top: 2px;
  font-weight: 600;
  line-height: 1.4;
}
.label-listen   { color: var(--blue); }
.label-silence  { color: var(--amber); }
.label-wrong    { color: var(--red); }
.label-advance  { color: var(--green); }
.label-pivot    { color: var(--purple); }
.label-caution  { color: var(--red); }

.response-content {
  font-size: 14px;
  color: var(--muted);
  line-height: 1.65;
  font-weight: 300;
}
.response-content strong { color: var(--text); font-weight: 600; }
.response-content em { color: var(--amber); font-style: normal; font-weight: 500; }
.response-content .red-text { color: var(--red); font-weight: 600; }
.response-content .green-text { color: var(--green); font-weight: 600; }
.response-content .purple-text { color: var(--purple); font-weight: 500; }

/* Speech bubble styling for spoken lines */
.say {
  background: rgba(255,255,255,0.03);
  border-left: 2px solid var(--purple);
  border-radius: 0 6px 6px 0;
  padding: 10px 14px;
  margin-top: 8px;
  font-size: 14px;
  color: var(--text);
  font-style: italic;
  line-height: 1.6;
}
.say::before {
  content: '"';
  color: var(--purple);
  font-family: 'Playfair Display', serif;
  font-size: 18px;
  font-style: normal;
  margin-right: 3px;
}
.say::after {
  content: '"';
  color: var(--purple);
  font-family: 'Playfair Display', serif;
  font-size: 18px;
  font-style: normal;
  margin-left: 2px;
}

/* ── IDEAL ANSWER BOX ── */
.ideal-answer {
  background: rgba(34,197,94,0.05);
  border: 1px solid rgba(34,197,94,0.15);
  border-radius: 6px;
  padding: 10px 14px;
  margin-top: 8px;
  font-size: 13px;
  color: rgba(34,197,94,0.85);
  line-height: 1.6;
}
.ideal-answer::before {
  content: 'Ideal response: ';
  font-weight: 600;
  color: var(--green);
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.1em;
}

/* ── DEBATE SPECIAL ── */
.debate-guide {
  background: var(--surface);
  border: 1px solid var(--border);
  border-radius: 12px;
  overflow: hidden;
  margin-bottom: 16px;
}
.debate-guide-header {
  background: var(--surface2);
  padding: 14px 22px;
  border-bottom: 1px solid var(--border);
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  color: var(--dim);
}
.debate-sides {
  display: grid;
  grid-template-columns: 1fr 1fr;
  border-bottom: 1px solid var(--border);
}
.debate-side {
  padding: 18px 22px;
  border-right: 1px solid var(--border);
}
.debate-side:last-child { border-right: none; }
.debate-side h4 {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  margin-bottom: 12px;
  font-weight: 600;
}
.pro h4 { color: var(--green); }
.con h4 { color: var(--red); }
.debate-side ul {
  list-style: none;
  display: flex;
  flex-direction: column;
  gap: 8px;
}
.debate-side li {
  font-size: 13px;
  color: var(--muted);
  padding-left: 16px;
  position: relative;
  line-height: 1.5;
}
.pro li::before  { content: '+'; position: absolute; left: 0; color: var(--green); font-weight: 800; }
.con li::before  { content: '−'; position: absolute; left: 0; color: var(--red); font-weight: 800; }
.debate-footer {
  padding: 16px 22px;
}

/* ── DIVIDER ── */
.rule {
  width: 40px; height: 2px;
  background: var(--amber);
  margin: 20px 0;
  border-radius: 2px;
}

/* ── FOOTER ── */
.page-footer {
  margin-top: 64px;
  padding: 28px 44px;
  border-top: 1px solid var(--border);
  display: flex;
  justify-content: space-between;
  align-items: center;
  flex-wrap: wrap;
  gap: 12px;
}
.pf-left { font-family: 'JetBrains Mono', monospace; font-size: 11px; color: var(--dim); }
.pf-right { font-size: 12px; color: var(--dim); }

@media (max-width: 680px) {
  .container { padding: 0 20px; }
  .hero { padding: 40px 20px 36px; }
  .response-row { grid-template-columns: 1fr; gap: 6px; }
  .debate-sides { grid-template-columns: 1fr; }
  .debate-side { border-right: none; border-bottom: 1px solid var(--border); }
}
</style>
</head>
<body>

<div class="hero">
  <div class="hero-eyebrow">A Tale of Two Trials — FXI Journal Club</div>
  <h1>Moderator Guide:<br><em>Every Discussion Prompt</em></h1>
  <p class="hero-sub">Statements, cold-call openers, ideal responses, and advance cues for each question asked across all 24 slides. Organized by slide number.</p>
  <div class="hero-meta">
    <div class="hmeta"><div class="hmeta-label">Slide deck</div><div class="hmeta-val">slides.html</div></div>
    <div class="hmeta"><div class="hmeta-label">Reference doc</div><div class="hmeta-val">index.html</div></div>
    <div class="hmeta"><div class="hmeta-label">Discussion prompts</div><div class="hmeta-val">17 questions across 7 slides</div></div>
    <div class="hmeta"><div class="hmeta-label">Estimated discussion time</div><div class="hmeta-val">~22 of 45 minutes</div></div>
  </div>
</div>

<a class="back-link" href="slides.html">← Back to Slides</a>

<div class="container">

  <div class="how-to">
    <span class="htitle">How to use this guide</span>
    Each question block shows four things: <strong>Listen for</strong> — what a well-prepared resident should say; <strong>If silent</strong> — the cold-call prompt that unlocks the room; <strong>If wrong</strong> — how to redirect without shutting the person down; and <strong>Advance with</strong> — the synthesizing statement you use to move to the next slide. The verbatim lines marked in purple are meant to be said nearly word-for-word. Everything else is a guide.
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 06 — OPENING CASE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-amber">Slide 04</div>
      <div>
        <div class="section-title">Opening Clinical Case</div>
        <div class="section-subtitle">78F · AF · ESRD · GI bleed 4 months ago · Aspiration pneumonia</div>
      </div>
    </div>

    <!-- Q1 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q1</div>
        <div class="q-text">Who would anticoagulate this patient today? Show of hands.</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">A divided room — ideally 30–50% of hands up. Unanimity in either direction is a red flag that residents aren't engaging honestly. You want disagreement.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If only 1–2 hands</div>
          <div class="response-content">
            <div class="say">I'm going to hold that number. Remember: Cardiology put in a consult asking you to anticoagulate. That attending thinks it's worth considering. What would you need to believe to say yes?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If near-unanimous yes</div>
          <div class="response-content">
            <div class="say">That surprises me. She bled 4 months ago and hematology said indefinite hold. Walk me through your reasoning — because that attending is on the other side of this phone call.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">Hold that number. We're coming back to this exact patient at the end of the session. The answer may be different then.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q2 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q2</div>
        <div class="q-text">What single factor is most driving your decision — stroke risk, bleed history, or renal function?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Most residents will say <strong>bleeding history</strong>. Good. The more interesting answer is that all three factors are interconnected — ESRD worsens bleeding risk independent of anticoagulation, while also elevating stroke risk. The CHA₂DS₂-VASc is 5, meaning annual stroke risk is ~7–10% untreated.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If silent</div>
          <div class="response-content">
            <div class="say">Let me make it concrete. Her CHA₂DS₂-VASc is 5. That's approximately a 7–9% annual stroke risk without anticoagulation. Her GI bleed was 4 months ago. Those two numbers have to fight each other. Which one wins in your head?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-wrong">If someone says "renal function"</div>
          <div class="response-content">
            <div class="say">That's a good instinct — and worth unpacking. Apixaban is labeled for dialysis patients, so technically we have an option. Does the renal issue go away if dosing is solved?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">This is exactly the clinical bind that creates millions of under-anticoagulated AF patients nationwide. The bleeding history is real — but so is the stroke risk. What if the bleeding risk equation could be fundamentally changed?</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q3 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q3</div>
        <div class="q-text">Would your answer change if the GI bleed was 12 months ago instead of 4?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Ideally, residents recognize there is no clean evidence-based cutoff — the 3-month, 6-month, and 12-month thresholds cited in practice are largely expert opinion. The AHA/ACC and CHEST guidelines offer timeframe guidance for specific bleed subtypes, but a cecal AVM has a very high recurrence risk independent of time elapsed.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If everyone just says "yes, I'd restart"</div>
          <div class="response-content">
            <div class="say">What's the evidence basis for 12 months being safer than 4? Where does that threshold come from? Is there an RCT for that number, or is it gestalt?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">Key teaching point</div>
          <div class="response-content">The cecal AVM matters more than the time elapsed. AVMs have a rebleed rate of approximately <strong>25–35% per year</strong> regardless of when the initial bleed occurred. This is not a lesion where "enough time has passed" meaningfully changes the risk calculus unless the AVM has been treated.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">There's no clean evidence-based answer here. That's precisely why three to four million patients like her get no anticoagulation at all. Let's talk about what the coagulation cascade tells us about whether that has to remain true.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 11 — KEY PHYSIOLOGY INSIGHT
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-blue">Slide 10</div>
      <div>
        <div class="section-title">Physiology Discussion</div>
        <div class="section-subtitle">After the hemostasis / thrombosis comparison slide</div>
      </div>
    </div>

    <!-- Q4 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon blue">Q4</div>
        <div class="q-text">Why doesn't hemophilia C cause spontaneous bleeding like hemophilia A?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">The answer is pathway architecture. In hemophilia A (FVIII deficiency) and B (FIX deficiency), the intrinsic pathway is required to sustain thrombin generation after the extrinsic pathway's initial burst — particularly in joints, where TF expression is low. In FXI deficiency, the extrinsic pathway is fully intact and generates the initial hemostatic plug. FXI is needed for amplification and propagation, not initiation. Spontaneous hemarthroses require failure of initiation, not just propagation.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If no one answers</div>
          <div class="response-content">
            <div class="say">Think about where each factor sits. FVIII and FIX are in the tenase complex — they're downstream of FXI. If they're gone, what happens to the entire intrinsic pathway? Now compare that to losing FXI specifically — what still works?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Deeper cold call</div>
          <div class="response-content">
            <div class="say">Why do hemophilia C patients bleed with dental extractions and urologic surgery but not with a laceration? What's different about those anatomic sites?</div>
            <div style="margin-top:8px;" class="ideal-answer">High local fibrinolytic activity (urokinase in urine, tPA in oral mucosa) degrades the initial clot before propagation can compensate. FXI-dependent amplification is necessary to keep pace with fibrinolysis — which explains the site-specific bleeding phenotype.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">So the extrinsic pathway gives you the first plug. FXI amplifies and sustains it. In normal wound healing, the first plug is usually enough — which is why FXI-deficient patients don't bleed spontaneously. But in AF-related thrombus, where there's no wound and no TF trigger, stasis and contact activation drive clot formation almost entirely through the intrinsic pathway — exactly where FXI operates. This is why it's the right target.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q5 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon blue">Q5</div>
        <div class="q-text">What types of thrombosis do you predict FXI inhibitors work best for — arterial, venous, or cardioembolic?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content"><strong>Venous and cardioembolic</strong> — and ideally a resident who can explain why. Both are driven primarily by stasis and contact activation (the intrinsic pathway), not by plaque rupture or platelet activation (the primary drivers in acute arterial events).</div>
        </div>
        <div class="response-row">
          <div class="response-label label-wrong">If someone says "arterial"</div>
          <div class="response-content">
            <div class="say">Interesting. Think about what drives an arterial MI — atherosclerotic plaque rupture, platelet activation, tissue factor exposure. Which pathway is that? Now think about left atrial thrombus in AF — the left atrial appendage is a low-flow, stasis-driven environment. Which pathway is dominant there?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">Why this matters for the trial results</div>
          <div class="response-content">This mechanistic prediction is exactly what makes OCEANIC-AF's failure complex. The drug should theoretically work for cardioembolic stroke — the right setting. The failure may be dose-dependent rather than mechanism-dependent. This tension is worth flagging before moving to the trials.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">Venous and cardioembolic — correct. Which means AF is theoretically the ideal indication. So let's talk about what actually happened when we tested these drugs in AF patients. The results were not what anyone expected.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 20 — OCEANIC-AF CRITIQUE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-red">Slide 15</div>
      <div>
        <div class="section-title">Critical Appraisal — OCEANIC-AF</div>
        <div class="section-subtitle">Asundexian vs. apixaban · Stopped for inferiority</div>
      </div>
    </div>

    <!-- Q6 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon red">Q6</div>
        <div class="q-text">Noninferiority design: is it possible asundexian was designed to demonstrate safety while assuming efficacy would hold?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Residents who understand that noninferiority trials implicitly assume the experimental drug is <em>probably as good</em> as the comparator — they're testing whether it's <strong>not unacceptably worse</strong>. OCEANIC-AF's design assumed asundexian would preserve enough of apixaban's stroke prevention while reducing bleeding. The phase 2 efficacy signal was treated as sufficient proof of concept to power the trial for safety, not superiority.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If silent</div>
          <div class="response-content">
            <div class="say">In a noninferiority trial, what is the implicit assumption about the experimental drug before you even start enrolling? What has to be true for that design to be ethical?</div>
            <div class="ideal-answer">You have to believe the drug is probably effective — you're just quantifying how much worse it's allowed to be. If you suspected it might be meaningfully inferior, a superiority trial or a placebo-controlled trial would be more appropriate.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">The harder question</div>
          <div class="response-content">
            <div class="say">Who decided on the noninferiority margin? Bayer did. And a noninferiority margin that is too generous means the drug could be inferior in clinically meaningful ways and still "pass." Ask yourself: was the margin defined by what patients would accept, or by what the sponsor needed to get approval?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">Noninferiority trials can be designed to pass even with a clinically inferior drug if the margin is generous enough. The fact that OCEANIC-AF failed even this relatively low bar tells you something important — the magnitude of inferiority wasn't close. This wasn't a borderline result.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q7 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon red">Q7</div>
        <div class="q-text">OCEANIC-AF was stopped for inferiority. How does this differ from trials stopped for benefit? How should it affect interpretation?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">The key distinction is direction of bias. Trials stopped early for <strong>benefit</strong> inflate the apparent effect size — the winner's curse. Trials stopped early for <strong>inferiority</strong> are more straightforward: the drug was failing, and continuing would have caused harm by exposing more patients to inferior therapy. The estimate of inferiority is <em>less</em> subject to inflation because DSMBs are conservative about stopping for inferiority — they typically wait until the signal is unambiguous.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If silent</div>
          <div class="response-content">
            <div class="say">When a DSMB stops a trial early for benefit, what happens to the estimated treatment effect? Now flip it — when they stop for inferiority, in which direction does that bias the estimate of harm?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-wrong">If someone says "we can't trust the result"</div>
          <div class="response-content">
            <div class="say">That's a reasonable concern for trials stopped for benefit, but think it through here. DSMBs require overwhelming evidence of inferiority before stopping. If anything, the true effect is likely even more inferior than the point estimate. Can you think of a scenario where stopping early for inferiority would have inflated a negative result?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">When a DSMB stops for inferiority, they're saying: the evidence is so clear that continuing would be unethical. This result is not ambiguous. Asundexian at 50mg daily does not adequately prevent stroke in AF. The question is why — and that's where mechanism comes back in.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q8 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon red">Q8</div>
        <div class="q-text">Asundexian targets FXIa only. What mechanistic explanation accounts for inadequate stroke prevention?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Incomplete suppression of the amplification loop. FXIa inhibitors compete at the active site but leave FXI zymogen available for activation by thrombin (the feedback amplification loop — thrombin activates FXI, which generates more FXIa, which generates more thrombin). The dose of 50mg may not have achieved sustained, complete inhibition of FXIa activity throughout the dosing interval. At trough plasma levels, partial FXIa activity may be sufficient to drive cardioembolic thrombus propagation in high-risk AF patients.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Cold call prompt</div>
          <div class="response-content">
            <div class="say">Here's a hint. Asundexian has a half-life of about 20 hours but is dosed once daily. What happens to drug levels at hour 18, 20, 22? If you need sustained suppression of FXIa activity throughout the entire dosing interval to prevent left atrial appendage thrombus, what does partial inhibition at trough mean for stroke risk?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">The abelacimab contrast</div>
          <div class="response-content">
            <div class="say">Now compare abelacimab — it binds the FXI zymogen and blocks activation entirely. There's no partial suppression at trough because FXI itself is unavailable, not just FXIa. If you block the substrate, you don't need to worry about competitive inhibition kinetics.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The mechanistic explanation for asundexian's failure may be incomplete target suppression — either at peak dosing or trough. Whether a higher dose or twice-daily dosing would rescue efficacy is unknown and would require a new trial. That's an expensive question to answer. Which is why, when abelacimab's data came out, it mattered so much.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q9 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon red">Q9</div>
        <div class="q-text">Asundexian did reduce bleeding. Does this argue for dose optimization, or does it confirm FXIa inhibition is the wrong target?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">This is genuinely debated in the field. Both interpretations are defensible. The bleeding reduction proves the drug is <em>biologically active</em> at the FXI pathway — it's not inert. The efficacy failure may be dose-dependent rather than target-dependent. However, higher doses to improve stroke prevention could erase the bleeding advantage — the risk-benefit window may simply be too narrow for FXIa active-site inhibition at any dose.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If discussion stalls</div>
          <div class="response-content">
            <div class="say">Let's think about what a dose-response curve looks like for this drug. If you double the dose to improve FXIa suppression at trough, what happens to peak-level bleeding risk? Is there a dose where you get both adequate stroke prevention and bleeding benefit — or does improving one necessarily worsen the other?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">Watch LIBREXIA</div>
          <div class="response-content">
            <div class="say">Milvexian — also a FXIa inhibitor — is in Phase 3 now. If it fails too, that's strong evidence that the FXIa active site is simply the wrong target for stroke prevention. If it succeeds, dose and pharmacokinetics matter more than the target site. LIBREXIA-AF will answer this.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">We don't know yet. But here's what we do know: a different drug, targeting FXI upstream rather than FXIa downstream, was tested at the same time — in a smaller trial, in a harder patient population. Let's look at what happened.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 23 — AZALEA-TIMI 71 CRITIQUE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-green">Slide 18</div>
      <div>
        <div class="section-title">Critical Appraisal — AZALEA-TIMI 71</div>
        <div class="section-subtitle">Abelacimab vs. rivaroxaban · Stopped early for overwhelming safety benefit</div>
      </div>
    </div>

    <!-- Q10 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon green">Q10</div>
        <div class="q-text">The trial was stopped early for safety benefit. What is the statistical consequence? How does the winner's curse affect HR 0.33?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">When trials are stopped early at interim analyses, the observed treatment effect is systematically <strong>larger than the true effect</strong>. This occurs because interim looks are conducted multiple times — the trial is stopped when the data happens to look particularly favorable, which is a form of selection bias. The HR 0.33 (67% RRR) is likely an overestimate. Real-world data on abelacimab, if approved, will probably show a smaller but still clinically meaningful bleeding advantage — perhaps HR 0.45–0.55.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Cold call prompt</div>
          <div class="response-content">
            <div class="say">Imagine flipping a coin 10 times. You stop counting when you get 7 heads. If you repeat that experiment 1,000 times, what's the average number of heads in the trials you stopped at 7 or more? Is it 5, or is it higher? That's the winner's curse in a single sentence.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">How to frame it clinically</div>
          <div class="response-content">
            <div class="say">This doesn't mean abelacimab doesn't work. A real-world HR of 0.5 — a 50% reduction in major bleeding — is still extraordinary for a drug class. It means the point estimate in the press release is likely optimistic, and prescribers should expect real-world performance to be somewhat less dramatic.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">Every drug class goes through this. The early trials of statins, DOACs, and SGLT2 inhibitors all showed slightly inflated effect sizes that regressed in broader populations. The question isn't whether 0.33 is an overestimate — it probably is. The question is whether the true effect, whatever it is, is still clinically meaningful. For a class that's trying to expand anticoagulation to patients with nowhere to turn, even HR 0.5 changes the conversation.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q11 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon green">Q11</div>
        <div class="q-text">Stroke/SE was non-inferior, but the CI is wide (0.58–2.14). What can and cannot we conclude about stroke prevention vs. apixaban?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">The trial was <strong>not powered for stroke efficacy</strong> — only ~1,287 patients and ~1.8 years follow-up in a high-bleeding-risk population where absolute event rates are low. The wide CI (0.58–2.14) means abelacimab could be substantially better or worse than rivaroxaban for stroke — we genuinely cannot tell. The non-inferiority claim is weak because the confidence interval is so wide that it barely qualifies. It could easily include clinically meaningful inferiority.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If residents just say "non-inferior, so it works"</div>
          <div class="response-content">
            <div class="say">Look at the upper bound of that CI: 2.14. That means abelacimab could more than double the stroke risk compared to rivaroxaban and we couldn't rule it out with this trial's power. Is that the same level of evidence we used to approve apixaban? How many events were in each arm?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">The real-world implication</div>
          <div class="response-content">The FDA will need a larger, adequately powered efficacy trial before approval in most jurisdictions. LILAC's bleeding data is practice-changing. Its efficacy data is hypothesis-generating. These are not the same thing, and conflating them is a common error in how this trial is discussed.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">We know abelacimab dramatically reduces bleeding. We do not yet know if it adequately prevents stroke compared to apixaban — that trial hasn't been done. That is the single most important thing to say when a patient or colleague asks you if this drug works.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q12 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon green">Q12</div>
        <div class="q-text">The population was enriched for high-bleeding-risk. How does this affect external validity to a general AF population?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">The NNT of 14 is derived from a <em>high-risk population</em> where baseline bleeding rates are elevated. In average-risk AF patients on a DOAC, the baseline major bleeding rate is lower, so the absolute risk reduction would be smaller and the NNT would be higher. The drug's risk-benefit profile looks best in exactly the patients it was tested in — those who have already demonstrated high bleeding susceptibility.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Framing prompt</div>
          <div class="response-content">
            <div class="say">If a drug reduces relative bleeding risk by 67% in a population where baseline bleeding is 10%/year, what's the ARR? Now apply the same relative reduction to a population where baseline bleeding is 3%/year. How does the NNT change? What does that tell you about who should receive this drug first?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The drug was designed for, tested in, and will likely be most beneficial to patients with high baseline bleeding risk — exactly the patients currently getting no anticoagulation at all. For average-risk AF patients already tolerating apixaban, the benefit-risk equation is less clear. Which means patient selection will matter as much as the drug itself.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q13 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon green">Q13</div>
        <div class="q-text">Open-label design: rivaroxaban patients knew their drug. Does this introduce ascertainment bias for bleeding endpoints?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Open-label designs are vulnerable to performance bias and detection bias. Rivaroxaban patients (and their clinicians) knowing the drug could influence how actively they report or seek evaluation for bleeding symptoms. However, <strong>adjudication was blinded</strong> — a DSMB and endpoint committee reviewed outcomes without knowing treatment assignment. This partially mitigates but does not eliminate the risk, since the endpoint committee only adjudicates what's reported to them.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If no one brings up blinded adjudication</div>
          <div class="response-content">
            <div class="say">The paper says adjudication was blinded. What does that mean specifically — who was blinded, and at what stage of the process? If a patient on rivaroxaban has minor rectal bleeding and doesn't call their study coordinator, does blinded adjudication protect against that bias?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">Direction of bias</div>
          <div class="response-content">
            <div class="say">If there is ascertainment bias, which direction does it run? Are rivaroxaban patients more likely to over-report bleeding — making abelacimab look artificially better? Or under-report? Think about which group has more incentive to flag events.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The open-label limitation is real and acknowledged in the paper. It's an important caveat. But the magnitude of the bleeding signal — HR 0.33 — is large enough that moderate ascertainment bias is unlikely to explain it away entirely. If the true effect were HR 0.7, this critique would be more threatening. At HR 0.33, you'd need substantial differential reporting to nullify the result.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q14 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon green">Q14</div>
        <div class="q-text">Monthly SC injection vs. daily oral. Will real-world adherence differences affect stroke prevention in ways the trial couldn't detect?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">This cuts both ways. Monthly dosing could improve adherence — one missed injection is less consequential than missing daily pills. But monthly injections require a healthcare contact point (clinic, infusion center, visiting nurse) which not all patients have. In a dialysis population, the monthly HD visit creates a natural administration opportunity. In non-dialysis patients, access could be a barrier, especially in rural or underserved areas.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Prompt for rural/community context</div>
          <div class="response-content">
            <div class="say">Think about our patient population here. If someone misses their monthly abelacimab injection — maybe they couldn't get a ride, maybe they were hospitalized — how long until their FXI levels recover? Compare that to missing one dose of apixaban. Which lapse is more dangerous?</div>
            <div class="ideal-answer">Missing one apixaban dose: drug-level gap of ~24 hours, then restored. Missing one abelacimab injection: t½ is 30 days, so FXI remains substantially suppressed for weeks after the missed dose — actually providing a safety buffer against non-adherence, in contrast to short-acting drugs where gaps mean gaps in protection.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The long half-life that creates the reversal problem is actually a feature for adherence. A missed injection doesn't immediately expose the patient to stroke risk. That's a meaningful advantage in real-world community hospital settings where medication adherence is highly variable.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 27 — RETURN TO CASE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-amber">Slide 21</div>
      <div>
        <div class="section-title">Return to the Opening Case</div>
        <div class="section-subtitle">Reconsidering with LILAC data in hand</div>
      </div>
    </div>

    <!-- Q15 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q15</div>
        <div class="q-text">Abelacimab reduced major bleeding by 67% vs. rivaroxaban in patients exactly like her. Does this change your decision?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">A shift in the show-of-hands from slide 4. If more residents now say yes, the session has worked. Ideally, a resident can articulate <em>why</em> it changes their decision — not just because the bleeding risk is lower, but because the specific patient (ESRD, prior GI bleed, high CHA₂DS₂-VASc) sits at the intersection of the LILAC enrichment criteria.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If still resistant</div>
          <div class="response-content">
            <div class="say">Her annual untreated stroke risk is approximately 7–9%. If abelacimab provides non-inferior stroke protection at a major bleeding rate 67% lower than rivaroxaban, what is the expected number of major bleeds prevented per stroke avoided? Put numbers on it.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-caution">Caution if everyone says "yes, obvious"</div>
          <div class="response-content">
            <div class="say">Hold on — we still don't know if abelacimab prevents stroke as well as apixaban. LILAC compared to rivaroxaban and was powered for bleeding, not stroke. Is it possible we're trading a well-characterized stroke prevention drug for one with an uncertain efficacy profile? What are you actually promising this patient?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The question isn't "abelacimab vs. apixaban in a typical AF patient." It's "abelacimab vs. nothing" — because nothing is what this patient is currently getting. That reframe changes the math entirely.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q16 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q16</div>
        <div class="q-text">She's on HD. Abelacimab has no renal clearance. Does the ESRD factor disappear?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Partially. No renal clearance means no dose adjustment uncertainty — a significant advantage over apixaban (where ESRD dosing remains debated) and complete contraindication of rivaroxaban, dabigatran, and edoxaban. However, <strong>uremic platelet dysfunction</strong> in ESRD increases baseline bleeding risk independent of anticoagulation. The drug's clean renal profile doesn't eliminate bleeding risk — it just removes one variable.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">If residents say "yes, ESRD concern is gone"</div>
          <div class="response-content">
            <div class="say">Does the ESRD factor disappear entirely? Think about what ESRD does to platelet function independent of anticoagulation. Uremic platelet dysfunction exists on its own. Abelacimab's clean renal clearance removes one variable — which one does it remove, and which one does it leave?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">No renal clearance removes dosing uncertainty. It does not remove the elevated baseline bleeding risk that comes with renal failure. She's still a higher-risk patient — but the drug's pharmacokinetics are more predictable in her than any current DOAC.</div>
          </div>
        </div>
      </div>
    </div>

    <!-- Q17 -->
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon">Q17</div>
        <div class="q-text">She has no reversal option. Does that change your counseling? Your prescription decision?</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-listen">Listen for</div>
          <div class="response-content">Nuanced thinking: the absence of reversal is a real risk, but it must be weighed against what the drug provides. If the drug reduces ICH by ~90%, the most dangerous bleeding complication is largely prevented. The bleeding events that do occur — GI, urologic — are more manageable without reversal than ICH. The reversal gap matters most for <em>trauma</em> and <em>urgent surgery</em>, not necessarily for the predictable bleeding complications a GI bleeder has already demonstrated susceptibility to.</div>
        </div>
        <div class="response-row">
          <div class="response-label label-silence">Sharpen the question</div>
          <div class="response-content">
            <div class="say">She falls and sustains a subdural hematoma 3 weeks after her injection. You're the neurosurgery fellow taking the call. The drug has a 30-day half-life and there is no reversal agent. Walk me through your management. Does having that conversation in advance change whether you prescribe the drug?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">The proportionality point</div>
          <div class="response-content">
            <div class="say">Here's the proportionality argument: apixaban has reversal with andexanet, but andexanet costs $27,000 per treatment course and causes thrombotic complications in roughly 10% of patients. How often do you actually successfully reverse a DOAC in a major bleed, and how often does the bleed resolve with supportive care alone? Is the reversal gap larger in theory than in practice?</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">Advance with</div>
          <div class="response-content">
            <div class="say">The reversal gap is real and non-negotiable in your consent conversation. Whether it should be a deal-breaker depends on the patient's specific risk profile — how likely is she to have a neurosurgical emergency vs. a GI rebleed? Those questions don't have generic answers. They have to be worked out with this patient, in this context.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       SLIDE 28 — DEBATE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-purple">Slide 22</div>
      <div>
        <div class="section-title">Structured Debate — Full Moderator Guide</div>
        <div class="section-subtitle">Motion: Adopt FXI inhibitors as first-line for high-bleeding-risk AF upon approval</div>
      </div>
    </div>

    <div class="question-block">
      <div class="q-header">
        <div class="q-icon purple">Setup</div>
        <div class="q-text">Before opening the debate: framing the motion correctly</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-pivot">Opening frame</div>
          <div class="response-content">
            <div class="say">I want to be specific about the motion so we're all arguing the same thing. The motion is not "FXI inhibitors are better than DOACs for all AF patients." The motion is: <em>upon FDA approval of abelacimab, it should become first-line anticoagulation for patients with AF who have high bleeding risk — specifically those with prior major GI bleed, prior ICH, or ESRD.</em> Left side of the room argues for. Right side argues against. You have 60 seconds to talk to each other. Go.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-pivot">If time is short</div>
          <div class="response-content">You can run this as a single-pass format: pro side makes their best argument in 90 seconds, con side responds directly (not from their list — to what was actually said), then one rebuttal from each. Total: 4 minutes. Close with the synthesis statement below.</div>
        </div>
      </div>
    </div>

    <div class="debate-guide">
      <div class="debate-guide-header">Arguments and moderator counters for each position</div>
      <div class="debate-sides">
        <div class="debate-side pro">
          <h4>Pro — Likely Arguments + Your Response</h4>
          <ul>
            <li><strong>"67% bleeding reduction — nothing else achieves this."</strong><br><span style="color:var(--dim); font-size:12px;">Let them land this. It's correct and it's the strongest point.</span></li>
            <li><strong>"ICH near-eliminated — the most feared complication disappears."</strong><br><span style="color:var(--dim); font-size:12px;">Also correct. Push: "How confident are you in that number given trial size and early stopping?"</span></li>
            <li><strong>"These patients currently get nothing — anything is better."</strong><br><span style="color:var(--dim); font-size:12px;">Challenge: "Is that always true? Is an inadequately validated stroke prevention drug better than no drug if we don't know the efficacy?"</span></li>
            <li><strong>"No renal dosing complexity."</strong><br><span style="color:var(--dim); font-size:12px;">Correct. Let stand.</span></li>
            <li><strong>"Monthly dosing improves adherence."</strong><br><span style="color:var(--dim); font-size:12px;">Push: "Requires injection infrastructure. Who administers this in a non-dialysis patient in a rural community?"</span></li>
          </ul>
        </div>
        <div class="debate-side con">
          <h4>Con — Likely Arguments + Your Response</h4>
          <ul>
            <li><strong>"OCEANIC-AF proved this class can fail."</strong><br><span style="color:var(--dim); font-size:12px;">Correct — but make them articulate the mechanistic difference between asundexian and abelacimab.</span></li>
            <li><strong>"We don't know if it prevents stroke as well as apixaban."</strong><br><span style="color:var(--dim); font-size:12px;">Strongest con argument. Reinforce it: "The comparison to apixaban hasn't been done in a powered efficacy trial."</span></li>
            <li><strong>"No reversal agent."</strong><br><span style="color:var(--dim); font-size:12px;">Real. Challenge: "Does available reversal change actual clinical outcomes? How often is andexanet actually used successfully?"</span></li>
            <li><strong>"Trial stopped early — inflated effect size."</strong><br><span style="color:var(--dim); font-size:12px;">Correct methodology. Push: "By how much? Does a true HR of 0.5 still change your practice?"</span></li>
            <li><strong>"Cost and access unknown."</strong><br><span style="color:var(--dim); font-size:12px;">Legitimate practical concern but somewhat speculative. Ask: "Should efficacy/safety data drive formulary decisions before cost is known?"</span></li>
          </ul>
        </div>
      </div>
      <div class="debate-footer">
        <div class="response-row" style="padding: 0; grid-template-columns: 160px 1fr;">
          <div class="response-label label-advance">Close with</div>
          <div class="response-content">
            <div class="say">Both sides raised the same underlying question: we have compelling safety data and uncertain efficacy data. The debate isn't really pro vs. con FXI inhibitors — it's a debate about how much efficacy uncertainty you're willing to accept in exchange for a very large bleeding reduction, in a patient who currently has no options. That's the question the FDA will have to answer, and it's the question you'll face at the bedside. What single piece of additional data would resolve it for you?</div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- ════════════════════════════════════════════
       FINAL CLOSE
       ════════════════════════════════════════════ -->
  <div class="slide-section">
    <div class="section-header">
      <div class="slide-tag tag-dim">Slide 24</div>
      <div>
        <div class="section-title">Closing the Session</div>
        <div class="section-subtitle">After the takeaways slide</div>
      </div>
    </div>
    <div class="question-block">
      <div class="q-header">
        <div class="q-icon purple">Close</div>
        <div class="q-text">Final synthesis — landing the session</div>
      </div>
      <div class="q-body">
        <div class="response-row">
          <div class="response-label label-advance">If time allows: exit question</div>
          <div class="response-content">
            <div class="say">Go back to slide four in your head — the patient with AF, ESRD, and the cecal AVM bleed four months ago. At the beginning of this session, I asked for a show of hands. I'm not going to ask again. But I want you to walk out of here knowing that whatever your answer is, it should be informed by the specific evidence we discussed today — not by a general discomfort with anticoagulating the patient, and not by uncritical enthusiasm for a new drug class. The evidence is promising, incomplete, and genuinely uncertain. That's exactly where good clinical judgment lives.</div>
          </div>
        </div>
        <div class="response-row">
          <div class="response-label label-advance">If time is short</div>
          <div class="response-content">
            <div class="say">One sentence to leave you with: FXI inhibitors may change who we anticoagulate — but only if the efficacy data we don't yet have matches the safety data we do. Watch LIBREXIA-AF. That result will tell you whether this class has a future or whether LILAC was an outlier.</div>
          </div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /container -->

<div class="page-footer">
  <div class="pf-left">MODERATOR GUIDE · FXI INHIBITOR JOURNAL CLUB · 17 QUESTIONS</div>
  <div class="pf-right">Use alongside slides.html · Updated February 2026</div>
</div>

</body>
</html>
